{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T13:45:26Z","timestamp":1775483126225,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"French Center for Studies and Research on the Intensification of Diabetes Treatment","award":["French Center for Studies and Research on the Intensification of Diabetes Treatment (CERITD)"],"award-info":[{"award-number":["French Center for Studies and Research on the Intensification of Diabetes Treatment (CERITD)"]}]},{"name":"Diabeloop SA","award":["Diabeloop SA"],"award-info":[{"award-number":["Diabeloop SA"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-025-02780-5","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T10:16:23Z","timestamp":1766744183000},"page":"959-968","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and glycemic outcomes of DBLG1 coupled to the DANA-i pump in adults and adolescents with type 1 diabetes mellitus. The SP8 trial"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5123-7743","authenticated-orcid":false,"given":"Sylvia","family":"Franc","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6267-8058","authenticated-orcid":false,"given":"Y.","family":"Reznik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Amadou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9635-7674","authenticated-orcid":false,"given":"A.","family":"Penfornis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4301-5531","authenticated-orcid":false,"given":"P.","family":"Schaepelynck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8794-8990","authenticated-orcid":false,"given":"H.","family":"Hanaire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Delemer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Le Tallec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3759-3490","authenticated-orcid":false,"given":"J.","family":"Beltrand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Jeandidier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Bensaid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Orlando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4995-3913","authenticated-orcid":false,"given":"P.","family":"Hannaert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4378-0468","authenticated-orcid":false,"given":"P.-Y.","family":"Benhamou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6124-5712","authenticated-orcid":false,"given":"G.","family":"Charpentier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,26]]},"reference":[{"key":"2780_CR1","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1007\/s00125-021-05391-w","volume":"64","author":"CK Boughton","year":"2021","unstructured":"Boughton CK, Hovorka R (2021) New closed-loop insulin systems. Diabetologia 64:1007\u20131015","journal-title":"Diabetologia"},{"key":"2780_CR2","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1016\/S2589-7500(19)30003-2","volume":"1","author":"PY Benhamou","year":"2019","unstructured":"Benhamou PY, Franc S, Reznik Y et al (2019) Closed-loop insulin delivery in adults with type 1 diabetes in real-life conditions: a 12-week multicentre, open-label randomised controlled crossover trial. Lancet Digit Health 1:e17\u2013e25","journal-title":"Lancet Digit Health"},{"key":"2780_CR3","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1111\/dom.14442","volume":"23","author":"S Franc","year":"2021","unstructured":"Franc S, Benhamou PY, Borot S et al (2021) No more hypoglycaemia on days with physical activity and unrestricted diet when using a closed-loop system for 12 weeks: A post hoc secondary analysis of the multicentre, randomized controlled Diabeloop WP7 trial. Diabetes Obes Metab 23:2170\u20132176","journal-title":"Diabetes Obes Metab"},{"key":"2780_CR4","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1111\/dom.13898","volume":"22","author":"H Hanaire","year":"2020","unstructured":"Hanaire H, Franc S, Borot S et al (2020) Efficacy of the Diabeloop closed-loop system to improve glycaemic control in patients with type 1 diabetes exposed to gastronomic dinners or to sustained physical exercise. Diabetes Obes Metab 22:324\u2013334","journal-title":"Diabetes Obes Metab"},{"key":"2780_CR5","doi-asserted-by":"publisher","first-page":"e158","DOI":"10.1016\/S2589-7500(21)00271-5","volume":"4","author":"D Kariyawasam","year":"2022","unstructured":"Kariyawasam D, Morin C, Casteels K et al (2022) Hybrid closed-loop insulin delivery versus sensor-augmented pump therapy in children aged 6\u201312 years: a randomised, controlled, cross-over, non-inferiority trial. Lancet Digit Health 4:e158\u2013e168","journal-title":"Lancet Digit Health"},{"key":"2780_CR6","unstructured":"Diabeloop, Diabeloop obtains CE marking and launches new round of funding (2018). Available from: https:\/\/www.diabeloop.com\/media-press\/press-releases\/diabeloop-obtains-ce-marking-and-launches-new-round-of-funding-2"},{"key":"2780_CR7","unstructured":"SOOIL. SOOIL Diabecare Dana-i (2021) [cited 2025 february 23rd] Available from: https:\/\/www.sooil.com\/eng\/product\/"},{"key":"2780_CR8","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1007\/s40200-020-00547-8","volume":"19","author":"M Burnside","year":"2020","unstructured":"Burnside M, Lewis D, Crocket H et al (2020) CREATE (Community derived automated insulin delivery) trial. Randomised parallel arm open label clinical trial comparing automated insulin delivery using a mobile controller (AnyDANA-loop) with an open-source algorithm with sensor augmented pump therapy in type 1 diabetes. J Diabetes Metab Disord 19:1615\u20131629","journal-title":"J Diabetes Metab Disord"},{"key":"2780_CR9","first-page":"2007","volume":"387","author":"MJ Burnside","year":"2022","unstructured":"Burnside MJ, Williman JA, de Bock MI (2022) Open-Source automated insulin delivery in type 1 diabetes. Reply N Engl J Med 387:2007\u20132008","journal-title":"Reply N Engl J Med"},{"key":"2780_CR10","unstructured":"FDA (2023) Food and Drug Administration What is a Serious Adverse Event? [cited 2025 April 14th] Available from: https:\/\/www.fda.gov\/safety\/reporting-serious-problems-fda\/what-serious-adverse-event"},{"key":"2780_CR11","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.2337\/dc17-1600","volume":"40","author":"T Danne","year":"2017","unstructured":"Danne T, Nimri R, Battelino T et al (2017) International consensus on use of continuous glucose monitoring. Diabetes Care 40:1631\u20131640","journal-title":"Diabetes Care"},{"key":"2780_CR12","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.2337\/dc15-2716","volume":"39","author":"DM Maahs","year":"2016","unstructured":"Maahs DM, Buckingham BA, Castle JR et al (2016) Outcome measures for artificial pancreas clinical trials: A consensus report. Diabetes Care 39:1175\u20131179","journal-title":"Diabetes Care"},{"key":"2780_CR13","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.2337\/dc08-0545","volume":"31","author":"DM Nathan","year":"2008","unstructured":"Nathan DM, Kuenen J, Borg R et al (2008) Translating the A1C assay into estimated average glucose values. Diabetes Care 31:1473\u20131478","journal-title":"Diabetes Care"},{"key":"2780_CR14","first-page":"218","volume":"270","author":"A Lamer","year":"2020","unstructured":"Lamer A, Laurent G, Pelayo S et al (2020) Exploring patient path through Sankey diagram: A proof of concept. Stud Health Technol Inf 270:218\u2013222","journal-title":"Stud Health Technol Inf"},{"key":"2780_CR15","doi-asserted-by":"publisher","unstructured":"Jiao X, Shen Y, Chen Y (2022) Better TIR HbA1c, and less hypoglycemia in closed-loop insulin system in patients with type 1 diabetes: a meta-analysis. BMJ Open Diabetes Res Care 10(2):e002633. https:\/\/doi.org\/10.1136\/bmjdrc-2021-002633","DOI":"10.1136\/bmjdrc-2021-002633"},{"key":"2780_CR16","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.2337\/dc21-S006","volume":"44","author":"ADA. American Diabetes Association","year":"2020","unstructured":"ADA. American Diabetes Association (2020) 6. Glycemic targets: standards of medical care in Diabetes\u20142021. Diabetes Care 44:S73\u2013S84","journal-title":"Diabetes Care"},{"key":"2780_CR17","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.2337\/dci19-0028","volume":"42","author":"T Battelino","year":"2019","unstructured":"Battelino T, Danne T, Bergenstal RM et al (2019) Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care 42:1593\u20131603","journal-title":"Diabetes Care"},{"key":"2780_CR18","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1089\/dia.2021.0319","volume":"24","author":"AL Carlson","year":"2022","unstructured":"Carlson AL, Sherr JL, Shulman DI et al (2022) Safety and glycemic outcomes during the minimed advanced hybrid Closed-Loop system pivotal trial in adolescents and adults with type 1 diabetes. Diabetes Technol Ther 24:178\u2013189","journal-title":"Diabetes Technol Ther"},{"key":"2780_CR19","doi-asserted-by":"crossref","unstructured":"Singh R, Imberg H, Ahmadi SS et al (2024) Effects, Safety, and treatment experience of advanced hybrid Closed-Loop systems in clinical practice among adults living with type 1 diabetes. J Diabetes Sci Technol 19(6):1598-1607","DOI":"10.1177\/19322968241242386"},{"key":"2780_CR20","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1007\/s00125-023-06049-5","volume":"67","author":"J Jendle","year":"2024","unstructured":"Jendle J, Adolfsson P, Choudhary P et al (2024) A narrative commentary about interoperability in medical devices and data used in diabetes therapy from an academic EU\/UK\/US perspective. Diabetologia 67:236\u2013245","journal-title":"Diabetologia"},{"key":"2780_CR21","doi-asserted-by":"crossref","unstructured":"Aaron RE, Tian T, Yeung AM et al (2023) NIH fifth artificial pancreas workshop 2023: meeting report: the fifth artificial pancreas workshop: enabling fully Automation, Access, and adoption. J Diabetes Sci Technol 18(1):215-239","DOI":"10.1177\/19322968231201829"},{"key":"2780_CR22","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1089\/dia.2018.0308","volume":"21","author":"SM Anderson","year":"2019","unstructured":"Anderson SM, Dassau E, Raghinaru D et al (2019) The international diabetes Closed-Loop study: testing artificial pancreas component interoperability. Diabetes Technol Ther 21:73\u201380","journal-title":"Diabetes Technol Ther"},{"key":"2780_CR23","doi-asserted-by":"crossref","unstructured":"Deshpande S, Weinzimer SA, Gibbons K et al (2022) Feasibility and preliminary safety of Smartphone-Based automated insulin delivery in adolescents and children with type 1 diabetes. J Diabetes Sci Technol 18(2):363-37","DOI":"10.1177\/19322968221116384"},{"key":"2780_CR24","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1177\/19322968241271304","volume":"19","author":"DC Klonoff","year":"2025","unstructured":"Klonoff DC, Ho CN, Ayers A et al (2025) FDA interoperability Designation-Creating options for people with diabetes and pump companies: Regulatory, Technological, and commercial perspectives. J Diabetes Sci Technol 19:869\u2013874","journal-title":"J Diabetes Sci Technol"},{"key":"2780_CR25","doi-asserted-by":"crossref","unstructured":"Newman C, Hartnell S, Wilinska M et al (2025) Real-World evidence of the Cambridge hybrid Closed-Loop app with a novel Real-Time continuous glucose monitoring system. J Diabetes Sci Technol 19(1):165-168","DOI":"10.1177\/19322968231187915"},{"key":"2780_CR26","doi-asserted-by":"publisher","unstructured":"Geerts I, Benhalima K (2025) Use of advanced technology for the treatment of type 1 diabetes in pregnancy. Best Pract Res Clin Endocrinol Metab 39(6):102026.  https:\/\/doi.org\/10.1016\/j.beem.2025.102026","DOI":"10.1016\/j.beem.2025.102026"},{"key":"2780_CR27","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1089\/dia.2023.0262","volume":"25","author":"M Nwokolo","year":"2023","unstructured":"Nwokolo M, Lakshman R, Hartnell S et al (2023) CamAPS FX hybrid Closed-Loop with Ultra-Rapid Lispro compared with standard Lispro in adults with type 1 diabetes: A Double-Blind, Randomized, crossover study. Diabetes Technol Ther 25:856\u2013863","journal-title":"Diabetes Technol Ther"},{"key":"2780_CR28","doi-asserted-by":"publisher","first-page":"1596188","DOI":"10.3389\/fdgth.2025.1596188","volume":"7","author":"P Pujante","year":"2025","unstructured":"Pujante P, Garcia AV, Villa-Fernandez E et al (2025) One-year evaluation of automated insulin delivery systems in adults with type 1 diabetes. Front Digit Health 7:1596188","journal-title":"Front Digit Health"},{"key":"2780_CR29","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1111\/dom.15008","volume":"25","author":"PY Benhamou","year":"2023","unstructured":"Benhamou PY, Adenis A, Lebbad H et al (2023) One-year real-world performance of the DBLG1 closed-loop system: data from 3706 adult users with type 1 diabetes in Germany. Diabetes Obes Metab 25:1607\u20131613","journal-title":"Diabetes Obes Metab"},{"key":"2780_CR30","doi-asserted-by":"publisher","first-page":"844","DOI":"10.2337\/dc20-1809","volume":"44","author":"C Amadou","year":"2021","unstructured":"Amadou C, Franc S, Benhamou PY et al (2021) Diabeloop DBLG1 Closed-Loop system enables patients with type 1 diabetes to significantly improve their glycemic control in Real-Life situations without serious adverse events: 6-Month Follow-up. Diabetes Care 44:844\u2013846","journal-title":"Diabetes Care"},{"key":"2780_CR31","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/d41586-023-02648-9","volume":"620","author":"L Drew","year":"2023","unstructured":"Drew L (2023) A DIY \u2018bionic pancreas\u2019 is changing diabetes care - what\u2019s next? Nature 620:940\u2013941","journal-title":"Nature"},{"key":"2780_CR32","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1177\/1932296820901612","volume":"14","author":"E Renard","year":"2020","unstructured":"Renard E (2020) Certified interoperability allows a more secure move to the artificial pancreas through a new concept: Make-It-Yourself. J Diabetes Sci Technol 14:195\u2013197","journal-title":"J Diabetes Sci Technol"},{"key":"2780_CR33","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1089\/dia.2024.0073","volume":"26","author":"GP Forlenza","year":"2024","unstructured":"Forlenza GP, Tabatabai I, Lewis DM (2024) Point-Counterpoint: the need for Do-It-Yourself (DIY) open source (OS) AID systems in type 1 diabetes management. Diabetes Technol Ther 26:689\u2013699","journal-title":"Diabetes Technol Ther"},{"key":"2780_CR34","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s00592-020-01623-4","volume":"58","author":"NAM Asarani","year":"2021","unstructured":"Asarani NAM, Reynolds AN, Elbalshy M et al (2021) Efficacy, safety, and user experience of DIY or open-source artificial pancreas systems: a systematic review. Acta Diabetol 58:539\u2013547","journal-title":"Acta Diabetol"},{"key":"2780_CR35","doi-asserted-by":"publisher","first-page":"e0248965","DOI":"10.1371\/journal.pone.0248965","volume":"16","author":"A Gawrecki","year":"2021","unstructured":"Gawrecki A, Zozulinska-Ziolkiewicz D, Michalak MA et al (2021) Safety and glycemic outcomes of do-it-yourself AndroidAPS hybrid closed-loop system in adults with type 1 diabetes. PLoS ONE 16:e0248965","journal-title":"PLoS ONE"},{"key":"2780_CR36","first-page":"99A","volume":"106","author":"MH Ebell","year":"2022","unstructured":"Ebell MH (2022) Closed-Loop system improves glycemic control but not hypoglycemia for young children with type 1 diabetes mellitus. Am Fam Physician 106:99A\u201399B","journal-title":"Am Fam Physician"},{"key":"2780_CR37","doi-asserted-by":"publisher","first-page":"e074128","DOI":"10.1136\/bmjopen-2023-074128","volume":"13","author":"W Shang","year":"2023","unstructured":"Shang W, Wei L, Liu Y et al (2023) Impact of the COVID-19 pandemic on the conduct of non-COVID-19 clinical trials: protocol for a scoping review. BMJ Open 13:e074128","journal-title":"BMJ Open"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-025-02780-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-025-02780-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-025-02780-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T12:47:40Z","timestamp":1775479660000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-025-02780-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":37,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["2780"],"URL":"https:\/\/doi.org\/10.1007\/s40618-025-02780-5","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,26]]},"assertion":[{"value":"23 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SF is employed by CERITD and is a shareholder of Diabeloop. SF has received personal compensation for board participation and speaking fees from Novo Nordisk, Roche Diagnostics, Lifescan, Sanofi, Diabeloop and Eli Lilly, and received Research support from MSD Avenir financing fund outside of this work. YR declares consultant\/speaker fees from Medtronic, Insulet, Embecta, Abbott, Novo Nordisk, Eli-Lilly, Sanofi, TIMKL and Air Liquide Sant\u00e9 International. CA declares she has received speaker fees from Diabeloop SA in 2020. AP received consultant fees and\/or speaker fees from Abbott, Astra Zeneca, Bayer, Dexcom, Diabeloop, Glooko, Eli Lilly, Elivie, Insulet, Isis, Lifescan, Medtronic, Medtrum, Novo Nordisk, Sanofi Aventis, VitalAire, Ypsomed. PS has received speaker honoraria from Abbott, Sanofi and Novo Nordisk and has served on advisory board panels for Eli Lilly, Medtronic, TIMKL and Ypsomed. HH has received lecturer and scientific advisor fees from Insulet, Abbott, AstraZeneca, Novo Nordisk, Eli Lilly, Sanofi-Aventis, Lifescan, Medtronic, and research grants from Novo Nordisk, Lifescan, Abbott, Sanofi-Aventis. BD has received consultant fees and\/or speaker fees from Novo Nordisk, Sanofi, Eli Lilly and Medtronic. CLT declares no conflict of interest. JB received speaker honoraria from Novo Nordisk, Lilly, Medtronic, Sanofi Winthrop and Ypsomed and has served on advisory board panels for Abbott, Sanofi Winthrop, Medtronic, Lilly, Insulet and Ypsomed. NJ is a consultant at TIMKL and speaker at Lilly, Defymed and Lifescan for which she received honoraria. NJ is a member of the member of the scientific board at Sanofi, Diabeloop, TIMKL, Defymed and Lifescan. NJ served without fees on advisory boards for Defymed, Diabeloop and public services. LO was employed by CERITD and declares no conflict of interest. PH & SB declare no conflict of interest. PYB has received speaker honoraria from Abbott, Eli Lilly, Novo Nordisk, serves as CMO for Diabeloop SA, and has served on advisory board panels for Abbott, Insulet, Eli Lilly, Pharmasens and Novo Nordisk. GC is President of CERITD, co-founder of Diabeloop SA and a shareholder of Diabeloop.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The SP8 protocol was presented to the Ethics Committee of the Strasbourg Hospital (Est IV) on August 12, 2019, which issued a favorable opinion on December 6, 2019 (reference CPP 19.08.12.44905). The initial protocol and all its amendments were reviewed and approved by the ANSM (French National Agency for the Safety of Medicines and Health Products), which granted an authorization on November 8, 2019 (reference ANSM 2019-A01975-52).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All participants provided written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}